AMAG Pharmaceuticals (NASDAQ:AMAG) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.
Other research analysts have also recently issued research reports about the company. ValuEngine cut AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 21st. Janney Montgomery Scott cut AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a research report on Friday, June 15th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $18.00 price target (up previously from $17.00) on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. B. Riley raised AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $23.00 to $30.00 in a research report on Friday, June 15th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price target on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $22.87.
AMAG stock opened at $21.35 on Tuesday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.95 and a current ratio of 2.06. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $26.10. The firm has a market capitalization of $708.42 million, a price-to-earnings ratio of -3.74 and a beta of 0.48.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The business had revenue of $146.25 million during the quarter, compared to analysts’ expectations of $156.26 million. During the same period in the prior year, the firm posted ($0.40) EPS. The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. research analysts predict that AMAG Pharmaceuticals will post -3.43 earnings per share for the current year.
In related news, CEO William K. Heiden sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the chief executive officer now directly owns 328,015 shares in the company, valued at approximately $8,200,375. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.00% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board raised its stake in shares of AMAG Pharmaceuticals by 34.6% during the 2nd quarter. State of Wisconsin Investment Board now owns 35,000 shares of the specialty pharmaceutical company’s stock valued at $682,000 after purchasing an additional 9,000 shares during the period. Renaissance Technologies LLC raised its stake in shares of AMAG Pharmaceuticals by 6.2% during the 2nd quarter. Renaissance Technologies LLC now owns 1,641,100 shares of the specialty pharmaceutical company’s stock valued at $32,001,000 after purchasing an additional 96,300 shares during the period. Russell Investments Group Ltd. raised its stake in shares of AMAG Pharmaceuticals by 13.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,170,332 shares of the specialty pharmaceutical company’s stock valued at $22,878,000 after purchasing an additional 140,741 shares during the period. Sei Investments Co. raised its stake in shares of AMAG Pharmaceuticals by 1,695.3% during the 2nd quarter. Sei Investments Co. now owns 506,429 shares of the specialty pharmaceutical company’s stock valued at $9,876,000 after purchasing an additional 478,220 shares during the period. Finally, Hartford Investment Management Co. bought a new stake in shares of AMAG Pharmaceuticals during the 2nd quarter valued at $325,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What are the most popular ETFs
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.